Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C11H11Cl2NO3S |
| Molecular Weight | 308.181 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(C2=CC=C(Cl)C(Cl)=C2)S(=O)(=O)CCC1=O
InChI
InChIKey=FTBWWORDOHNJDB-UHFFFAOYSA-N
InChI=1S/C11H11Cl2NO3S/c1-14-10(15)4-5-18(16,17)11(14)7-2-3-8(12)9(13)6-7/h2-3,6,11H,4-5H2,1H3
Dichlormezanone is the skeletal muscle relaxant. This metathiazanone was found to have a mephenesin-like type of action characterized by paralyzing, anticonvulsant, and hypothermic activities. Dichlormezanone produced an ascending type of paralysis, associated with a marked ataxia. It has anti-electroshock and anti-chemoshock activities. It was found to be active after oral administration and to have a prolonged duration of action. The daily administration of sublethal doses of dichlormezanone to albino rats for 5 consecutive days produced only an initial loss of weight. No significant hematologic alteration or macroscopic lesion of any of the viscera, attributable to medication with either drug, was observed.
CNS Activity
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13635687
Daily dose - 45 mg/kg
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29756
Created by
admin on Mon Mar 31 18:20:05 GMT 2025 , Edited by admin on Mon Mar 31 18:20:05 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000082913
Created by
admin on Mon Mar 31 18:20:05 GMT 2025 , Edited by admin on Mon Mar 31 18:20:05 GMT 2025
|
PRIMARY | |||
|
TO4OC41XVI
Created by
admin on Mon Mar 31 18:20:05 GMT 2025 , Edited by admin on Mon Mar 31 18:20:05 GMT 2025
|
PRIMARY | |||
|
781
Created by
admin on Mon Mar 31 18:20:05 GMT 2025 , Edited by admin on Mon Mar 31 18:20:05 GMT 2025
|
PRIMARY | |||
|
C77250
Created by
admin on Mon Mar 31 18:20:05 GMT 2025 , Edited by admin on Mon Mar 31 18:20:05 GMT 2025
|
PRIMARY | |||
|
169109
Created by
admin on Mon Mar 31 18:20:05 GMT 2025 , Edited by admin on Mon Mar 31 18:20:05 GMT 2025
|
PRIMARY | |||
|
114676-16-3
Created by
admin on Mon Mar 31 18:20:05 GMT 2025 , Edited by admin on Mon Mar 31 18:20:05 GMT 2025
|
PRIMARY | |||
|
5571-97-1
Created by
admin on Mon Mar 31 18:20:05 GMT 2025 , Edited by admin on Mon Mar 31 18:20:05 GMT 2025
|
SUPERSEDED | |||
|
DTXSID50863561
Created by
admin on Mon Mar 31 18:20:05 GMT 2025 , Edited by admin on Mon Mar 31 18:20:05 GMT 2025
|
PRIMARY | |||
|
CHEMBL2106150
Created by
admin on Mon Mar 31 18:20:05 GMT 2025 , Edited by admin on Mon Mar 31 18:20:05 GMT 2025
|
PRIMARY | |||
|
SUB07084MIG
Created by
admin on Mon Mar 31 18:20:05 GMT 2025 , Edited by admin on Mon Mar 31 18:20:05 GMT 2025
|
PRIMARY | |||
|
71209
Created by
admin on Mon Mar 31 18:20:05 GMT 2025 , Edited by admin on Mon Mar 31 18:20:05 GMT 2025
|
PRIMARY |
ACTIVE MOIETY